Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FirstGuard was a medical technology company focused on the early detection of breast cancer through non-invasive screening methods. The company developed a proprietary thermal sensing technology, often referred to as the FirstGuard Breast Cancer Screening System, which utilized Digital Infrared Thermal Imaging (DITI) to identify physiological changes in breast tissue. Unlike traditional mammography, the FirstGuard system was designed to be radiation-free and painless, targeting younger women and those with dense breast tissue who might not be ideal candidates for standard screenings. While the technology showed promise in identifying metabolic activity associated with tumor growth, the company is no longer actively marketing the device as a primary screening tool in the current clinical landscape.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FirstGuard.